Cost–consequence analysis of fluticasone furoate/vilanterol 92/22 mcg for the management of COPD in the Spanish NHS
Laura Amanda Vallejo-Aparicio,1 Germán Peces-Barba,2 Alicia Gil,3 Alicia Huerta Hernandez1 1Market Access, GlaxoSmithKline, Tres Cantos, Madrid, Spain; 2IIS-Fundación Jiménez Díaz. CIBERES, Madrid, Spain; 3Omakase Consulting, Barcelona, Spain Objectives: T...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Book |
| Published: |
Dove Medical Press,
2018-09-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Internet
Connect to this object online.3rd Floor Main Library
| Call Number: |
A1234.567 |
|---|---|
| Copy 1 | Available |